This business information is not released now.


Back
This page is displayed by "Spiral" of PIPED BITS Co.,Ltd., which is a database management ASP service, our contracted partner.


GeneStem, Co. Ltd,
【Field/Business】
Pharmaceutical/Drug Discovery
Drug discovery support/Contract service
Medical care/Diagnosis/Medical equipment/Healthcare
last update:2017/9/21
Profile

Delegates :
Koji Kobayashi


Incorporated :
January  11 , 2011

Paid in Capital :
3 Million yen  

Employees :
5 人

Address :
1-1-3-267, Umeda, Kita-ku, Osaka OSAKA
〒530-0001

TEL/FAX :
90-8474-5002 / 6-6875-7227

URL:
http://www.genestem.co.jp/

Attachment :

Mission/Background :
GeneStem Co., Ltd., the venture company, has been established based on the scientific outcomes achieved by Professor Takakura (Department of Signal Transduction, Research Institute for Microbial Diseases, Osaka University) to return the profit to society since January 11th, 2011. We will advertise materials generated by cancer research, researches of vascular biology and regenerative medicine as well as screening technologies for the development of new therapeutics in vascular diseases including cancer.

Technology & Business
* We prepared antibodies against PSF1, PSF3 and SLD5, components of GINS complex which are critical for DNA replication. GINS components express on cancer cells especially malignant cancer cells such as cancer stem cells or cancer initiating cells. Therefore, these antibodies are useful as a tool of cancer research. Antibodies are commercially available from Iwaki Co., Ltd. (E-mail address for inquiry: bio@iwaki-kk.co.jp).
* We have succeeded in methods to visualize cancer stem cells in the tumor environment. We accept screening job to identify agents for killing cancer stem cells using this technology (E-mail address for inquiry: cscsc@genestem.co.jp).
* We accept on research jobs associating with vasculogenesis and angiogenesis for screening of anti- and/or pro-angiogenic factors (E-mail address for inquiry: angio@genestem.co.jp).
* We have developed medical and pharmaceutical products and health food based on our technology of cancer and vascular biology.

Products & Service
Products & Service Name
Stage
Outline
Milestone
Antibodies detecting cancer stem cells
Launched
Monoclonal antibodies against PSF1, PSF3 and SLD5 are commercially available from Iwaki Co., Ltd.
We are trying to increase other antibodies.
Screening service for anti-cancer agents
Service/Marketing
We judge the efficacy of your agents for cancer stem cells based on our original visualization technic of cancer stem cells.

Screening service relating to vascular formation/angiogenesis
Service/Marketing
We judge the efficacy of your agents for blood vessel formation based on in vitro and in vivo analysis.

Development of anti-cancer drugs regulating cancer stem cells
Discovery


Development of pharmaceutical products relating to vascular stabilization and integrity
Discovery


Highlights
i)\tAugust 2012: Our patent entitled “ Cancer stem cells expressing SLD5 highly” was registered as No. 5058336.
ii)\tJuly 2011: Our application entitled “Development of therapeutic drugs and methods in regulation of caner stem cells” for Osaka Foundation for Trade and Industry was accepted.
iii)\tMay 2011: Our technology for visualization of cancer stem cells was reported in a news paper (Nikkei: May 16th, 2011).
Hot news
Because we are obtaining cancer stem cells expressing high level of SLD5, we have been able to carry out screening for anti-cancer stem cell drugs based on visualization of cancer stem cells. Moreover, we have a lot of methods in in vitro and in vivo analysis of blood vessel formation to screen drugs for anti- or pro-angiogenesis. Please contact us concerning any questions about other methods beside evaluation methods described in our web site.
Alliance strategy
Collaboration for therapeutic drug development in the treatment of vascular diseases caused by vascular disruption and of cancers especially targeting cancer stem cells.

 
This page is displayed by "Spiral" of PIPED BITS Co.,Ltd., which is a database management ASP service, our contracted partner.